logo

Merrimack Pharmaceuticals, Inc. (MACK)



Trade MACK now with
  Date
  Headline
5/10/2019 7:38:47 AM Merrimack Pharma Q1 Net Loss $10.5 Mln Or $0.78/Shr Vs Loss $17.8 Mln Or $1.33/Shr Last Year
5/10/2019 7:30:00 AM Merrimack Reports First Quarter 2019 Financial Results (Press Release)
12/10/2018 5:03:07 PM Syneos Health Appoints John Dineen To Board Of Directors
11/7/2018 6:50:13 AM Merrimack Pharma Q3 Loss Per Share $0.30 Vs Loss $0.24 Last Year
10/19/2018 6:13:19 AM Merrimack Discontinues Phase 2 SHERLOC Study Of MM-121 In Patients With Non-Small Cell Lung Cancer Due To Futility
9/6/2018 6:51:02 AM Merrimack Completes Enrollment In Randomized Phase 2 SHERLOC Study Of MM-121 In NSCLC
8/7/2018 6:36:50 AM Merrimack Q2 Net Loss $17.8 Mln Or $1.33 Per Share Vs Net Loss $28.9 Mln Or $2.18 Per Share Last Year
6/25/2018 7:20:50 AM Merrimack Announces Top-Line Results From Randomized Phase 2 Trial Of MM-141 In Front-Line Metastatic Pancreatic Cancer
5/8/2018 6:27:26 AM Merrimack Pharma Q1 Net Loss From Operations $17.8 Mln Or $1.33/Shr Vs Loss $28.7 Mln Or $2.20/Shr Last Year
3/12/2018 6:30:20 AM Merrimack Pharma Q4 Loss Attributable To Cont Opns $11.8 Mln Or $0.89/Shr Vs Loss $40.1 Mln Or $2.93/Shr Last Year
3/12/2018 6:29:04 AM Merrimack Pharma Expands Enrollment In Ongoing Randomized Phase 2 SHERLOC Study Of MM-121 In Non-small Cell Lung Cancer
2/26/2018 6:57:02 AM Merrimack Doses First Patient In Randomized Phase 2 Clinical Study Of MM-121